MADRS score
Supernus Pharmaceuticals’ Depression Drug SPN-820 Fails to Meet Primary Endpoint in Phase 2b Trial
Supernus Pharmaceuticals, SPN-820, treatment-resistant depression, Phase 2b trial, clinical study failure, MADRS score, placebo effect
Actionable Insights Powered by AI
Supernus Pharmaceuticals, SPN-820, treatment-resistant depression, Phase 2b trial, clinical study failure, MADRS score, placebo effect